BMI View: Bahrain’s wealth will continue to attract research-based pharmaceutical manufacturers. We therefore expect the value of the country’s patented drug market to continue on its steady upward trajectory. However, annual growth rates of its generic counterpart will be considerably more impressive, despite coming off a very low base, as leading drugs lose their patent protection Headline Expenditure Projections ? Pharmaceuticals: BHD100mn (US$266mn) in 2012 to BHD114mn (US$304mn) in 2013; +14.2% in both local currency and US dollar terms. Forecast slightly up from Q213, on the back of more positive macroeconomic data. ? Healthcare: BHD398mn (US$1.06bn) in 2012 to BHD431mn …
Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=105160.
Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/bahrain-pharmaceuticals-and-healthcare-report-q3-2013-market-report.html.
No comments:
Post a Comment